Nimotuzumab for COVID-19: case series.
Immunotherapy
; 2021 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1528786
ABSTRACT
Background:
In COVID-19, EGFR production is upregulated in the alveolar epithelial cells. EGFR overexpression further activates STAT-3 and increases lung pathology. The EGFR pathway is also one of the major nodes in pulmonary fibrosis.Methods:
Nimotuzumab, a humanized anti-EGFR antibody, was used to treat three patients with severe or moderate COVID-19. The antibody was administered in combination with other drugs included in the national COVID-19 protocol.Results:
Nimotuzumab was well tolerated. IL-6 decreased from the first antibody infusion. Clinical symptoms significantly improved after nimotuzumab administration, and the CT scans at discharge showed major resolution of the lung lesions and no signs of fibrosis.Conclusion:
Safe anti-EGFR antibodies like nimotuzumab may modulate COVID-19-associated hyperinflammation and prevent fibrosis. Clinical Trial Registration RPCEC00000369 (RPCEC rpcec.sld.cu).
Lay abstract
Background:
In COVID-19, the protein EGFR is overactive in the infected lung cells.Methods:
Nimotuzumab, an anti-EGFR antibody, was used to treat three patients with severe or moderate COVID-19. The antibody was administered in combination with other drugs included in the national COVID-19 protocol.Results:
Nimotuzumab was safe. The most important inflammatory markers decreased from the first administration. The patients' clinical symptoms and imaging results improved significantly.Conclusion:
Anti-EGFR antibodies like nimotuzumab may contribute to the recovery of COVID-19 patients without long-term consequences.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Tipo de estudio:
Estudio pronóstico
/
Ensayo controlado aleatorizado
Tópicos:
Covid persistente
Idioma:
Inglés
Asunto de la revista:
Alergia e Inmunología
/
Terapeutica
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Imt-2021-0269
Similares
MEDLINE
...
LILACS
LIS